Print Page | Sign In | Join
News & Press
Filter news by category:

Read about recent events, essential information and the latest community news.

Displaying page 5 of 27
1  |  2  |  3  |  4  |  5  |  6  |  7  |  8  |  9  |  10  >   >>   >| 

Scientific Advancements
Tuesday, January 30, 2024   (0 Comments - view/add)
Vaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases »
Vaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of Flo...
Monday, January 29, 2024   (0 Comments - view/add)
Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer’s Disease fr »
Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer’s Disease from the U.S. Patent and...
Monday, January 29, 2024   (0 Comments - view/add)
Longeveron Receives Notice of United States Patent Allowance for the Technology Behind its Lead Inve »
Longeveron Receives Notice of United States Patent Allowance for the Technology Behind its Lead Investigation Product Lome...
Thursday, January 25, 2024   (0 Comments - view/add)
In the War on Cancer, Tampa General Hospital Cancer Institute Employs AI in its Newly Established Ce »
In the War on Cancer, Tampa General Hospital Cancer Institute Employs AI in its Newly Established Center for Precision Rad...
Wednesday, January 24, 2024   (0 Comments - view/add)
How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder (GAD) Cond »
How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder (GAD) Condition FN Media...
Wednesday, January 24, 2024   (0 Comments - view/add)
ZyVersa Therapeutics Announces Peer-Reviewed Article Supporting the Therapeutic Potential of Targeti »
ZyVersa Therapeutics Announces Peer-Reviewed Article Supporting the Therapeutic Potential of Targeting ASC Specks During P...
Wednesday, January 24, 2024   (0 Comments - view/add)
AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampli »
AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment...
Tuesday, January 23, 2024   (0 Comments - view/add)
Psilera Announces Lead Indication for PSIL-006: Behavioral Variant Frontotemporal Dementia (bvFTD) »
Psilera Announces Lead Indication for PSIL-006: Behavioral Variant Frontotemporal Dementia (bvFTD) TAMPA, Fla....
Tuesday, January 23, 2024   (0 Comments - view/add)
NAYA Biosciences To Acquire Clinical Stage Gene Therapy Program for Leber's Hereditary Optic Neuropa »
NAYA Biosciences To Acquire Clinical Stage Gene Therapy Program for Leber's Hereditary Optic Neuropathy (LHON) J...
Monday, January 22, 2024   (0 Comments - view/add)
AIM ImmunoTech Announces that the First Subject is Enrolled in the Phase 1b/2 Study Evaluating Ampli »
AIM ImmunoTech Announces that the First Subject is Enrolled in the Phase 1b/2 Study Evaluating Ampligen® in Combination wi...
Thursday, January 18, 2024   (0 Comments - view/add)
Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Tria »
Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Ca...
Wednesday, January 17, 2024   (0 Comments - view/add)
FDA Clearance Granted for First AI-Powered Medical Device to Detect All Three Common Skin Cancers (M »
FDA Clearance Granted for First AI-Powered Medical Device to Detect All Three Common Skin Cancers (Melanoma, Basal Ce...
Wednesday, January 17, 2024   (0 Comments - view/add)
Smart Meter Builds on Role as Innovator in Cellular Remote Patient Monitoring »
Smart Meter Builds on Role as Innovator in Cellular Remote Patient Monitoring New patents awarded for cellular-enable...
Wednesday, January 17, 2024   (0 Comments - view/add)
ZyVersa Therapeutics Highlights Peer-Reviewed Article Linking Inflammasome Activation to Triple-Nega »
ZyVersa Therapeutics Highlights Peer-Reviewed Article Linking Inflammasome Activation to Triple-Negative Breast Cancer Bra...
Tuesday, January 16, 2024   (0 Comments - view/add)
Cyrano Therapeutics Secures $9.0 Million Series B Financing to Advanc »
Cyrano Therapeutics Secures $9.0 Million Series B Financing to Advance Clinical Development of CYR-064 for Treatment of Po...
Monday, January 15, 2024   (0 Comments - view/add)
Arthrex Launches Online Hub for Minimally Invasive Surgical Treatment Options With Nano Arthroscopy »
Arthrex Launches Online Hub for Minimally Invasive Surgical Treatment Options With Nano Arthroscopy The Nano Experie...
Friday, January 12, 2024   (0 Comments - view/add)
ProleevaMax Unleashes Innovative Organic Supplement Targeting Arthritic Pain: A Holistic Approach to »
ProleevaMax Unleashes Innovative Organic Supplement Targeting Arthritic Pain: A Holistic Approach to Pain Management P...
Wednesday, January 10, 2024   (0 Comments - view/add)
AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in »
AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with Astr...
Monday, January 8, 2024   (0 Comments - view/add)
Cybin Announces Positive Topline Data from Phase 1 Studies of Proprietary Deuterated DMT Molecules C »
Cybin Announces Positive Topline Data from Phase 1 Studies of Proprietary Deuterated DMT Molecules CYB004 and SPL028...
Monday, January 8, 2024   (0 Comments - view/add)
Aegle Therapeutics Corp. Announces Positive Data for the First Patient in a Phase 1/2a Clinical Tria »
Aegle Therapeutics Corp. Announces Positive Data for the First Patient in a Phase 1/2a Clinical Trial Dosed With AGLE-102™...
Monday, January 8, 2024   (0 Comments - view/add)
Zevra Therapeutics Receives FDA Acceptance of Resubmission of NDA for Arimoclomol as a Treatment for »
Zevra Therapeutics Receives FDA Acceptance of Resubmission of NDA for Arimoclomol as a Treatment for Niemann-Pick Disease...
Monday, January 8, 2024   (0 Comments - view/add)
Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened I »
Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (...
Thursday, January 4, 2024   (0 Comments - view/add)
POTENTIAL BREAKTHROUGH FOR ALZHEIMER'S TREATMENT: FOCUSED ULTRASOUND COMBINED WITH MONOCLONAL ANTIBO »
POTENTIAL BREAKTHROUGH FOR ALZHEIMER'S TREATMENT: FOCUSED ULTRASOUND COMBINED WITH MONOCLONAL ANTIBODIES MAY SLOW DISEASE...
Tuesday, January 2, 2024   (0 Comments - view/add)
Immorta Bio Announces Personalized Progenitor Cell Platform for Organ Specific Regeneration »
Immorta Bio Announces Personalized Progenitor Cell Platform for Organ Specific Regeneration Unique Tissue Creating Ce...
Tuesday, January 2, 2024   (0 Comments - view/add)
Oragenics Completes Acquisition of Odyssey Health’s Neurological Assets »
Oragenics Completes Acquisition of Odyssey Health’s Neurological Assets Adds Clinical-Stage Product Pipeline, Expand...
Wednesday, December 27, 2023   (0 Comments - view/add)
Zevra Therapeutics Announces Resubmission of Arimoclomol New Drug Application to the U.S. Food and D »
Zevra Therapeutics Announces Resubmission of Arimoclomol New Drug Application to the U.S. Food and Drug Administration...
Thursday, December 14, 2023   (0 Comments - view/add)
ZyVersa Therapeutics Engages CRO, George Clinical, for Phase 2a Clinical Trial for Cholesterol Efflu »
ZyVersa Therapeutics Engages CRO, George Clinical, for Phase 2a Clinical Trial for Cholesterol Efflux Mediator VAR 20...
Thursday, December 7, 2023   (0 Comments - view/add)
ZyVersa Therapeutics Announces Publication Demonstrating That Plasma Levels of NLRP3 Inflammasomes C »
ZyVersa Therapeutics Announces Publication Demonstrating That Plasma Levels of NLRP3 Inflammasomes Correlate with Progress...
Wednesday, December 6, 2023   (0 Comments - view/add)
New Clinical Data Demonstrate >90 Percent Area Reduction in Diabetic Foot Ulcers within 12 Weeks or »
New Clinical Data Demonstrate >90 Percent Area Reduction in Diabetic Foot Ulcers within 12 Weeks or less Using Novel Om...
Wednesday, November 29, 2023   (0 Comments - view/add)
Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical Development »
Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical Development November 29, 202...
Monday, November 27, 2023   (0 Comments - view/add)
ADvantage Therapeutics Has Commenced Enrollment for Its Phase 2b Clinical Trial of AD04™ for Treatme »
ADvantage Therapeutics Has Commenced Enrollment for Its Phase 2b Clinical Trial of AD04™ for Treatment of Alzheimer’s Dise...
Tuesday, November 21, 2023   (0 Comments - view/add)
AIM ImmunoTech Completes Treatment of Last Subject in Phase 2 Study Evaluating Ampligen® for the Tre »
AIM ImmunoTech Completes Treatment of Last Subject in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID C...
Tuesday, November 21, 2023   (0 Comments - view/add)
New Study of an AI-Powered Spectroscopy Device Shows Promise for Skin Cancer Detection »
New Study of an AI-Powered Spectroscopy Device Shows Promise for Skin Cancer Detection November 21, 2023 01:51 PM Eas...
Monday, November 20, 2023   (0 Comments - view/add)
Dyadic’s C1 Platform to be Used to Produce Vaccines for Humans and Animals in Africa »
Dyadic’s C1 Platform to be Used to Produce Vaccines for Humans and Animals in Africa November 20, 2023 08:30 ET|...
Monday, November 20, 2023   (0 Comments - view/add)
Exactech AI Platform Surpasses 100,000 Joint Replacement Surgeries Worldwide »
Exactech AI Platform Surpasses 100,000 Joint Replacement Surgeries Worldwide November 20, 2023 09:00 AM Eastern Stand...

Displaying page 5 of 27
1  |  2  |  3  |  4  |  5  |  6  |  7  |  8  |  9  |  10  >   >>   >| 

About BioFlorida

BioFlorida is the voice of Florida's life sciences industry, representing 8,600 establishments and research organizations in the BioPharma, MedTech, Digital Health and Health Systems that collectively employ nearly 107,000 Floridians. Source: TEConomy/BIO (released 2022)